Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease

Long-acting muscarinic antagonists (LAMAs), along with long-acting β(2)-agonists (LABAs), are the mainstay for treatment of patients with COPD. Glycopyrrolate, or glycopyrronium bromide, like other LAMAs, inhibits parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashkin, Donald P, Gross, Nicholas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003532/
https://www.ncbi.nlm.nih.gov/pubmed/29928118
http://dx.doi.org/10.2147/COPD.S162646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003532/
https://www.ncbi.nlm.nih.gov/pubmed/29928118
http://dx.doi.org/10.2147/COPD.S162646

Ejemplares similares